Sun, 8 Nov 2026 · LIVE
Updated Oct 29, 2026 · 19:27
India News Updated Oct 29, 2026

Government bars import of medicines with under one year shelf life

The Central Government has barred the import of medicines with less than one year of remaining shelf life under the Drugs (Thirteenth Amendment) Rules, 2026. The Health Ministry notification, published in the Official Gazette on October 28, 2026, amends Rule 31 of the Drugs Rules, 1945, while allowing biological drugs and radiopharmaceuticals to use 60 per cent of their labelled shelf life. The change was finalised after consultation with the Drugs Technical Advisory Board and consideration of public objections and suggestions on the June 22, 2026 draft.

Govt bars import of medicines with less than one year of remaining shelf life

New Delhi, October 29

The Central Government has barred the import of medicines with less than one year of remaining shelf life, while allowing a separate provision for biological drugs and radiopharmaceuticals, according to a notification issued by the Ministry of Health and Family Welfare.

The new rule, notified under the Drugs (Thirteenth Amendment) Rules, 2026, amends Rule 31 of the Drugs Rules, 1945, and has come into effect from the date of its publication in the Official Gazette on October 28, 2026.

"The licensing authority shall not allow the import of any drug having less than one year residual shelf-life period as on the date of import," the ministry said in the Gazette notification.

The amendment means that medicines covered by the general requirement must have at least one year of shelf life remaining when they are imported into India.

However, the government has provided a separate provision for biological drugs and radiopharmaceuticals, under which 60 per cent of the shelf life mentioned on the product label may be allowed.

The notification states, "in case of biological drugs and Radiopharmaceuticals, Sixty percent of the labelled shelf-life may be allowed."

According to the ministry, the amendment was finalised after consultation with the Drugs Technical Advisory Board and consideration of public feedback on the draft rules.

The government had earlier published the draft amendment on June 22, 2026, inviting objections and suggestions from affected stakeholders within 30 days of the Gazette copies being made available to the public.

"Objections and suggestions received from the public on the said draft rules have been considered by the Central Government," the notification stated.

— ANI

Reader’s Guide · AI-assisted, based only on the report above

What the report makes clear: The notification sets a one-year minimum residual shelf life for most imported drugs, with a separate 60 per cent labelled shelf-life allowance for biological drugs and radiopharmaceuticals.

Still open: The report does not yet say how the rule will be enforced at ports, whether existing import consignments get any transition period, or what it means for drug prices and availability.

Another way to look at it: A longer required shelf life protects patients from near-expiry stock but may shrink the supply of some imported medicines and raise costs.

Does a one-year shelf-life rule for imports help patients or risk shortages?

Reader Voices

Leave a comment

Be kind. Add to the conversation. 0/50
Thank you — your comment has been submitted.
JS blocked